Patents by Inventor Yujiro Hayashi

Yujiro Hayashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10981956
    Abstract: A peptide fragment isolated from proline-rich protein 4 (PRP4) has a neuroprotective action. The peptide can be a neuroprotective drug in a preventive or alleviative pharmaceutical composition. The peptide can be used in a neuropathic treatment.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 20, 2021
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi Nakajima, Mamiko Machida, Yujiro Hayashi
  • Patent number: 10971695
    Abstract: A multilayer reflection electrode film includes a Ag film that is formed of Ag or an Ag alloy; and a transparent conductive oxide film that is disposed on the Ag film, in which the transparent conductive oxide film is formed of an oxide that includes Zn and Ga and further includes one element or two or more elements selected from the group consisting of Sn, Y, and Ti.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: April 6, 2021
    Assignee: MITSUBISHI MATERIALS CORPORATION
    Inventors: Hiromi Nakazawa, Hiroshi Ishii, Yuto Toshimori, Atsushi Saito, Yujiro Hayashi
  • Publication number: 20200299332
    Abstract: The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This is based on the finding that a peptide fragment isolated from proline-rich protein 4 (PRP4) has a neuroprotective action.
    Type: Application
    Filed: March 30, 2017
    Publication date: September 24, 2020
    Applicant: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi NAKAJIMA, Mamiko MACHIDA, Yujiro HAYASHI
  • Patent number: 10660934
    Abstract: A peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing the peptide, and a preventive or alleviative pharmaceutical composition. The peptide comprises proline-rich protein 4 having the sequence of SEQ ID NO:1 or a partial sequence thereof, or a modified sequence thereof, which has a neuroprotective action.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: May 26, 2020
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi Nakajima, Mamiko Machida, Yujiro Hayashi
  • Publication number: 20190111104
    Abstract: The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This is based on the finding that a peptide fragment isolated from proline-rich protein 4 (PRP4) has a neuroprotective action.
    Type: Application
    Filed: March 30, 2017
    Publication date: April 18, 2019
    Applicant: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi NAKAJIMA, Mamiko MACHIDA, Yujiro HAYASHI
  • Publication number: 20190105872
    Abstract: A multilayer transparent conductive film is provided, including: a Ag film that is formed of Ag or a Ag alloy; and a transparent conductive oxide film that is disposed on two opposite surfaces of the Ag film, in which the transparent conductive oxide film is formed of an oxide including Zn, Ga, and Ti.
    Type: Application
    Filed: March 22, 2017
    Publication date: April 11, 2019
    Inventors: Hiromi Nakazawa, Hiroshi Ishii, Yuto Toshimori, Atsushi Saito, Yujiro Hayashi
  • Publication number: 20190103580
    Abstract: A multilayer reflection electrode film includes a Ag film that is formed of Ag or an Ag alloy; and a transparent conductive oxide film that is disposed on the Ag film, in which the transparent conductive oxide film is formed of an oxide that includes Zn and Ga and further includes one element or two or more elements selected from the group consisting of Sn, Y, and Ti.
    Type: Application
    Filed: March 22, 2017
    Publication date: April 4, 2019
    Inventors: Hiromi Nakazawa, Hiroshi Ishii, Yuto Toshimori, Atsushi Saito, Yujiro Hayashi
  • Patent number: 9139514
    Abstract: Disclosed are a process suited to large scale synthesis with high yield for producing oseltamivir phosphate, in which a preparation of oseltamivir phosphate which is highly safe as a pharmaceutical product can be produced, and an intermediate compound for producing oseltamivir phosphate. In this production process, an intermediate compound represented by general formula (V) is synthesized by employing Michael reaction/Michael reaction/Horner-Wadsworth-Emmons reaction, and oseltamivir phosphate is produced by converting the substituent groups in this intermediate compound.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: September 22, 2015
    Assignee: Sumitomo Chemical Company, Ltd.
    Inventors: Yujiro Hayashi, Hayato Ishikawa
  • Publication number: 20150238570
    Abstract: An object of the present invention is to provide a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc. The present invention provides a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc., the agents etc. comprising desacyl ghrelin or its derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: September 2, 2011
    Publication date: August 27, 2015
    Applicants: UNIVERSITY OF MIYAZAKI, DAIICHI SANKYO COMPANY, LIMITED, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Noboru Murakami, Keiko Nakahara, Kenji Kangawa, Yujiro Hayashi
  • Patent number: 9078868
    Abstract: An object of the present invention is to provide a therapeutic agent for accelerating recovery to accelerate a return to normal physical conditions by administering to an animal not in good health and under medical treatment, a treatment method, and the like. There is provided a therapeutic agent for accelerating recovery for animal use to accelerate the improvement of a physical condition of an animal under medical treatment which has a decreased activity (vigor) and is exhausted, which contains ghrelin or a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient and improves one or more of evaluation parameters consisting of activity (vigor), blood cell test values, biochemical test values, body temperature, the degree of anger or anxiety, and respiratory rate.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: July 14, 2015
    Assignees: UNIVERSITY OF MIYAZAKI, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Noboru Murakami, Keiko Nakahara, Kenji Kangawa, Yujiro Hayashi
  • Patent number: 8962889
    Abstract: The invention relates to a method of producing optically active ?-aminoaldehyde compound (3) by reacting imine compound (1-1) or sulfone compound (1-2) with aldehyde compound (2) in the presence of an optically active pyrrolidine compound. wherein each symbol is as defined in the specification.
    Type: Grant
    Filed: October 9, 2011
    Date of Patent: February 24, 2015
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Yujiro Hayashi
  • Patent number: 8742176
    Abstract: The invention relates to a method of producing optically active 4-chloro-3-hydroxybutanal compound (2) by reacting chloroacetaldehyde with aldehyde compound (1) in the presence of optically active pyrrolidine compound (5). wherein each symbol is as defined in the specification.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: June 3, 2014
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Yujiro Hayashi
  • Patent number: 8729294
    Abstract: The present invention provides a production method of optically active 3-substituted-3-formyl-2-hydroxypropanoic acid compound (4), which includes a step of reacting glyoxylic acid compound (1-1) or (1-2) with aldehyde (2) in the presence of optically active pyrrolidine compound (3); wherein each symbol is as defined in the specification.
    Type: Grant
    Filed: May 30, 2011
    Date of Patent: May 20, 2014
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Yujiro Hayashi
  • Patent number: 8716500
    Abstract: The present invention provides a method that allows production of stereospecific and asymmetrical five-membered ring-containing compounds serving as synthetic intermediates for formation of five-membered rings of prostaglandins and the like, with high yield and excellent stereoselectivity in terms of diastereoselectivity and enantioselectivity in a short process without requiring troublesome procedures such as optical resolution.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: May 6, 2014
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventor: Yujiro Hayashi
  • Publication number: 20140051874
    Abstract: The present invention provides a method that allows production of stereospecific and asymmetrical five-membered ring-containing compounds serving as synthetic intermediates for formation of five-membered rings of prostaglandins and the like, with high yield and excellent stereoselectivity in terms of diastereoselectivity and enantioselectivity in a short process without requiring troublesome procedures such as optical resolution.
    Type: Application
    Filed: April 27, 2012
    Publication date: February 20, 2014
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: Yujiro Hayashi
  • Publication number: 20130296600
    Abstract: Disclosed are a process suited to large scale synthesis with high yield for producing oseltamivir phosphate, in which a preparation of oseltamivir phosphate which is highly safe as a pharmaceutical product can be produced, and an intermediate compound for producing oseltamivir phosphate. In this production process, an intermediate compound represented by general formula (V) is synthesized by employing Michael reaction/Michael reaction/Horner-Wadsworth-Emmons reaction, and oseltamivir phosphate is produced by converting the substituent groups in this intermediate compound.
    Type: Application
    Filed: July 2, 2013
    Publication date: November 7, 2013
    Inventors: Yujiro Hayashi, Hayato Ishikawa
  • Publication number: 20130217901
    Abstract: The invention relates to a method of producing optically active 4-chloro-3-hydroxybutanal compound (2) by reacting chloroacetaldehyde with aldehyde compound (1) in the presence of optically active pyrrolidine compound (5). wherein each symbol is as defined in the specification.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 22, 2013
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Yujiro Hayashi
  • Publication number: 20130211139
    Abstract: The invention relates to a method of producing optically active ?-aminoaldehyde compound (3) by reacting imine compound (1-1) or sulfone compound (1-2) with aldehyde compound (2) in the presence of an optically active pyrrolidine compound. wherein each symbol is as defined in the specification.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 15, 2013
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Yujiro Hayashi
  • Patent number: 8501980
    Abstract: Disclosed are a process suited to large scale synthesis with high yield for producing oseltamivir phosphate, in which a preparation of oseltamivir phosphate which is highly safe as a pharmaceutical product can be produced, and an intermediate compound for producing oseltamivir phosphate. In this production process, an intermediate compound represented by general formula (V) is synthesized by employing Michael reaction/Michael reaction/Horner-Wadsworth-Emmons reaction, and oseltamivir phosphate is produced by converting the substituent groups in this intermediate compound.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: August 6, 2013
    Assignee: Sumitomo Chemical Company, Ltd.
    Inventors: Yujiro Hayashi, Hayato Ishikawa
  • Publication number: 20130137880
    Abstract: The present invention provides a production method of optically active 3-substituted-3-formyl-2-hydroxypropanoic acid compound (4), which includes a step of reacting glyoxylic acid compound (1-1) or (1-2) with aldehyde (2) in the presence of optically active pyrrolidine compound (3); wherein each symbol is as defined in the specification.
    Type: Application
    Filed: May 30, 2011
    Publication date: May 30, 2013
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Yujiro Hayashi